Strategic Partnerships Digital Diagnostics has a proven track record of forming high-profile collaborations with healthcare providers and labs (OSF HealthCare, Magrabi Health, LabCorp) to deploy LumineticsCore, indicating strong appetite from large networks for autonomous AI retinal diagnostics. Leverage these relationship patterns to target similar hospital systems, academic medical centers, and large diagnostic networks seeking scalable AI screening.

Global Expansion Recent news shows deployment in multiple regions (Magrabi in Riyadh, southeast US rollout, partnerships with diverse institutions), signaling momentum and readiness for international expansion. Focus sales efforts on markets with high diabetic retinopathy prevalence, robust payer ecosystems, and supportive regulatory pathways for autonomous AI diagnostics.

Financial Strength With a Series B of $75M and a revenue range of $10M–$25M, Digital Diagnostics has significant investor backing and growing top-line potential. This supports enterprise sales cycles to large healthcare players and enables multi-site deployments, managed services, and ongoing software updates across networks.

Autonomous AI Advantage Flagship product LumineticsCore is FDA-authorized for autonomous diabetic retinopathy diagnosis, positioning the company as a trusted vendor for fully automated screening workflows. Opportunities exist to upsell to additional diagnostic capabilities, integrate with existing EMR workflows, and offer expanded AI-based screening across other ophthalmic and neurological indicators.

Market Demand Strong demand signals from credible partners and initiatives to democratize care align with payer and provider incentives to reduce costs, improve access, and prevent vision loss. Sales leverage this by offering ROI-focused proposals that quantify reduced clinician workload, earlier intervention, and scalable screening across high-volume sites.